Cracker Barrel CEO: GLP-1s Haven't Affected Our Business -- Market Talk

Dow Jones
06/10
 

1826 ET - Cracker Barrel hasn't seen any effects of growing adoption of GLP-1 weight-loss drugs on its sales, Chief Executive Officer Julie Masino says on an analyst call. "We have been actively monitoring GLP-1s for over a year now," she says. "We have not seen any measurable impact at Cracker Barrel to date." She adds that the company offers portion flexibility, substantial protein offerings, and lighter options on its menu. (elias.schisgall@wsj.com)

 

(END) Dow Jones Newswires

June 09, 2026 18:26 ET (22:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10